Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 74

1.

Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J.

Lancet. 2012 Nov 3;380(9853):1559-67. doi: 10.1016/S0140-6736(12)61428-7. Epub 2012 Sep 11.

PMID:
22975340
[PubMed - indexed for MEDLINE]
2.

Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo.

Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E.

Virology. 2012 Jul 20;429(1):12-20. doi: 10.1016/j.virol.2012.03.003. Epub 2012 Apr 25.

PMID:
22537810
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.

de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM.

Proc Natl Acad Sci U S A. 2012 May 8;109(19):7439-44. doi: 10.1073/pnas.1200566109. Epub 2012 Apr 12.

PMID:
22499787
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody.

Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA.

Structure. 2012 Feb 8;20(2):303-14. doi: 10.1016/j.str.2012.01.001. Epub 2012 Jan 26.

PMID:
22285214
[PubMed - indexed for MEDLINE]
Free Article
5.

Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay.

Lin HE, Tsai WY, Liu IJ, Li PC, Liao MY, Tsai JJ, Wu YC, Lai CY, Lu CH, Huang JH, Chang GJ, Wu HC, Wang WK.

PLoS Negl Trop Dis. 2012 Jan;6(1):e1447. doi: 10.1371/journal.pntd.0001447. Epub 2012 Jan 3.

PMID:
22235356
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Evaluation of the traditional and revised WHO classifications of Dengue disease severity.

Narvaez F, Gutierrez G, Pérez MA, Elizondo D, Nuñez A, Balmaseda A, Harris E.

PLoS Negl Trop Dis. 2011 Nov;5(11):e1397. doi: 10.1371/journal.pntd.0001397. Epub 2011 Nov 8.

PMID:
22087348
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J.

Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13. Review.

PMID:
21745521
[PubMed - indexed for MEDLINE]
8.

A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus.

Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC.

PLoS Pathog. 2011 Jun;7(6):e1002111. doi: 10.1371/journal.ppat.1002111. Epub 2011 Jun 30.

PMID:
21738473
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.

de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM.

PLoS Negl Trop Dis. 2011 Jun;5(6):e1188. doi: 10.1371/journal.pntd.0001188. Epub 2011 Jun 21. Erratum in: PLoS Negl Trop Dis. 2011 Aug;5(8). doi: 10.1371/annotation/f585335f-ff77-40ae-a8b6-ad6019af31aa. Brian, James [corrected to Brien, James D].

PMID:
21713020
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Immune response to dengue virus and prospects for a vaccine.

Murphy BR, Whitehead SS.

Annu Rev Immunol. 2011;29:587-619. doi: 10.1146/annurev-immunol-031210-101315. Review.

PMID:
21219187
[PubMed - indexed for MEDLINE]
11.

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.

Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH.

Pediatr Infect Dis J. 2010 Oct 29. [Epub ahead of print]

PMID:
21042231
[PubMed - as supplied by publisher]
12.

An in-depth analysis of original antigenic sin in dengue virus infection.

Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, Waiyaiya E, Tran HB, Cowper AE, Chotiyarnwong P, Grimes JM, Yoksan S, Malasit P, Simmons CP, Mongkolsapaya J, Screaton GR.

J Virol. 2011 Jan;85(1):410-21. doi: 10.1128/JVI.01826-10. Epub 2010 Oct 27. Erratum in: J Virol. 2011 Nov;85(22):12100. Chotiyarnwon, Pojchong [corrected to Chotiyarnwong, Pojchong].

PMID:
20980526
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354.

Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, Chipman PR, Kuhn RJ, Diamond MS, Rossmann MG.

Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18950-5. doi: 10.1073/pnas.1011036107. Epub 2010 Oct 18.

PMID:
20956322
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F.

Cell Host Microbe. 2010 Sep 16;8(3):271-83. doi: 10.1016/j.chom.2010.08.007.

PMID:
20833378
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Mutations of an antibody binding energy hot spot on domain III of the dengue 2 envelope glycoprotein exploited for neutralization escape.

Gromowski GD, Roehrig JT, Diamond MS, Lee JC, Pitcher TJ, Barrett AD.

Virology. 2010 Nov 25;407(2):237-46. doi: 10.1016/j.virol.2010.06.044. Epub 2010 Sep 15.

PMID:
20832836
[PubMed - indexed for MEDLINE]
Free Article
16.

Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, Williams KL, Johnson S, Rico-Hesse R, Harris E, Pierson TC, Fremont DH, Diamond MS.

J Virol. 2010 Sep;84(18):9227-39. doi: 10.1128/JVI.01087-10. Epub 2010 Jun 30.

PMID:
20592088
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Cross-reacting antibodies enhance dengue virus infection in humans.

Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, Limpitikul W, Puttikhunt C, Edwards C, Duangchinda T, Supasa S, Chawansuntati K, Malasit P, Mongkolsapaya J, Screaton G.

Science. 2010 May 7;328(5979):745-8. doi: 10.1126/science.1185181. Erratum in: Science. 2010 Jul 9;329(5988):142.

PMID:
20448183
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III.

Matsui K, Gromowski GD, Li L, Barrett AD.

J Gen Virol. 2010 Sep;91(Pt 9):2249-53. doi: 10.1099/vir.0.021220-0. Epub 2010 May 5.

PMID:
20444995
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E.

PLoS Pathog. 2010 Feb 12;6(2):e1000790. doi: 10.1371/journal.ppat.1000790.

PMID:
20168989
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.

Zellweger RM, Prestwood TR, Shresta S.

Cell Host Microbe. 2010 Feb 18;7(2):128-39. doi: 10.1016/j.chom.2010.01.004.

PMID:
20153282
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk